Christopher O. McGovern

1.3k total citations
20 papers, 680 citations indexed

About

Christopher O. McGovern is a scholar working on Oncology, Epidemiology and Surgery. According to data from OpenAlex, Christopher O. McGovern has authored 20 papers receiving a total of 680 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Epidemiology and 5 papers in Surgery. Recurrent topics in Christopher O. McGovern's work include Pancreatic and Hepatic Oncology Research (8 papers), Neuroendocrine Tumor Research Advances (8 papers) and Lung Cancer Research Studies (4 papers). Christopher O. McGovern is often cited by papers focused on Pancreatic and Hepatic Oncology Research (8 papers), Neuroendocrine Tumor Research Advances (8 papers) and Lung Cancer Research Studies (4 papers). Christopher O. McGovern collaborates with scholars based in United States and Puerto Rico. Christopher O. McGovern's co-authors include Jill P. Smith, Gail L. Matters, Mark Kester, James H. Adair, Brian M. Barth, James M. Kaiser, Erhan İ. Altınoğlu, Sriram S. Shanmugavelandy, Francesca Ruggiero and Sandra I. Bingaman and has published in prestigious journals such as ACS Nano, Gastroenterology and PLoS ONE.

In The Last Decade

Christopher O. McGovern

20 papers receiving 673 citations

Peers

Countries citing papers authored by Christopher O. McGovern

Since Specialization

Citations

This map shows the geographic impact of Christopher O. McGovern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher O. McGovern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher O. McGovern more than expected).

Fields of papers citing papers by Christopher O. McGovern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher O. McGovern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher O. McGovern. The network helps show where Christopher O. McGovern may publish in the future.

Co-authorship network of co-authors of Christopher O. McGovern

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher O. McGovern. A scholar is included among the top collaborators of Christopher O. McGovern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher O. McGovern. Christopher O. McGovern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CCK Receptor Inhibition Reduces Pancreatic Tumor Fibrosis and Promotes Nanoparticle Delivery 2024 ·Biomedicines ·Thomas Abraham, (unknown), Christopher O. McGovern, John F. Harms, (unknown), (unknown), (unknown), Jennifer L. Gray, Deborah F. Kelly, James H. Adair, Gail L. Matters	1
2	Preferential uptake of antibody targeted calcium phosphosilicate nanoparticles by metastatic triple negative breast cancer cells in co-cultures of human metastatic breast cancer cells plus bone osteoblasts 2021 ·Nanomedicine Nanotechnology Biology and Medicine ·Karen M. Bussard, (unknown), (unknown), (unknown), (unknown), Welley Siu Loc, (unknown), Zi‐Kui Liu, (unknown), (unknown), Andrea M. Mastro, Alison B. Shupp, Christopher O. McGovern, Gail L. Matters, James H. Adair	5
3	Aptamer-Targeted Calcium Phosphosilicate Nanoparticles for Effective Imaging of Pancreatic and Prostate Cancer 2021 ·International Journal of Nanomedicine ·Thomas Abraham, Christopher O. McGovern, (unknown), (unknown), James H. Adair, Gail L. Matters	15
4	Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer 2017 ·Nanomedicine Nanotechnology Biology and Medicine ·Welley Siu Loc, (unknown), (unknown), Gail L. Matters, Christopher O. McGovern, Thomas Abraham, Todd E. Fox, (unknown), Xiaomeng Tang, (unknown), (unknown), Gary A. Clawson, Jill P. Smith, Peter J. Butler, Mark Kester, James H. Adair	12
5	"Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma 2017 ·PLoS ONE ·Gary A. Clawson, Gail L. Matters, Ping Xin, Christopher O. McGovern, Eric Wafula, Claude W. dePamphilis, (unknown), Joyce Wong, (unknown), (unknown), (unknown), Yuka Imamura Kawasawa, Zhen Du, Loren Honaas, Thomas Abraham	53
6	Germline Mutation of the CCK Receptor: A Novel Biomarker for Pancreas Cancer 2016 ·Clinical and Translational Gastroenterology ·(unknown), Gail L. Matters, Christopher O. McGovern, Jiangang Liao, (unknown), Jill P. Smith	4
7	A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma 2016 ·Nucleic Acid Therapeutics ·Gary A. Clawson, Thomas Abraham, Weihua Pan, Xiaomeng Tang, (unknown), Christopher O. McGovern, Welley Siu Loc, Jill P. Smith, Peter J. Butler, Mark Kester, James H. Adair, Gail L. Matters	36
8	Cholecystokinin Mediates Progression and Metastasis of Pancreatic Cancer Associated with Dietary Fat 2014 ·Digestive Diseases and Sciences ·Gail L. Matters, Timothy K. Cooper, Christopher O. McGovern, (unknown), Jiangang Liao, Brian M. Barth, Mark Kester, Jill P. Smith	30
9	Cholecystokinin Receptor Antagonist Halts Progression of Pancreatic Cancer Precursor Lesions and Fibrosis in Mice 2014 ·Pancreas ·Jill P. Smith, Timothy K. Cooper, Christopher O. McGovern, (unknown), Qing Zhong, Jiangang Liao, Alfredo Molinolo, J. Silvio Gutkind, Gail L. Matters	35
10	Blockade of the CCK receptor inhibits progression of early PanIN lesions to pancreatic cancer in the Pdx1-Cre, LSL/KrasG12D mouse 2013 ·Pancreatology ·Gail L. Matters, Timothy K. Cooper, (unknown), Christopher O. McGovern, Jiangang Liao, Jill P. Smith	2
11	Endogenous cholecystokinin (CCK) expression in human pancreatic cancer 2013 ·Pancreatology ·(unknown), Christopher O. McGovern, Gail L. Matters, Jill P. Smith	1
12	PhotoImmunoNanoTherapy Reveals an Anticancer Role for Sphingosine Kinase 2 and Dihydrosphingosine-1-Phosphate 2013 ·ACS Nano ·Brian M. Barth, Sriram S. Shanmugavelandy, James M. Kaiser, Christopher O. McGovern, Erhan İ. Altınoğlu, (unknown), Jeremy A. Hengst, (unknown), (unknown), Todd E. Fox, Jill P. Smith, Timothy M. Ritty, James H. Adair, Mark Kester	29
13	A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer 2012 ·Cancer Biology & Therapy ·Jill P. Smith, John F. Harms, Gail L. Matters, Christopher O. McGovern, Francesca Ruggiero, Jiangang Liao, Kristin Fino, (unknown), (unknown), John A. Phillips	15
14	Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis 2012 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·Kristin Fino, Gail L. Matters, Christopher O. McGovern, (unknown), Jill P. Smith	27
15	Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled Trial 2011 ·Digestive Diseases and Sciences ·Jill P. Smith, Sandra I. Bingaman, Francesca Ruggiero, David T. Mauger, Aparna Mukherjee, Christopher O. McGovern, Ian S. Zagon	89
16	Targeted Indocyanine-Green-Loaded Calcium Phosphosilicate Nanoparticles for In Vivo Photodynamic Therapy of Leukemia 2011 ·ACS Nano ·Brian M. Barth, Erhan İ. Altınoğlu, Sriram S. Shanmugavelandy, James M. Kaiser, (unknown), Nicole A. DiVittore, Christopher O. McGovern, (unknown), (unknown), James H. Adair, Thomas P. Loughran, David F. Claxton, Mark Kester	157
17	646 Naltrexone Therapy Improves Activity and Promotes Mucosal Healing in Active Crohn's Disease: A Placebo-Controlled Trial 2010 ·Gastroenterology ·Jill P. Smith, Sandra I. Bingaman, Francesca Ruggiero, David T. Mauger, Aparna Mukherjee, Christopher O. McGovern, Ian S. Zagon	5
18	Bioconjugation of Calcium Phosphosilicate Composite Nanoparticles for Selective Targeting of Human Breast and Pancreatic Cancers In Vivo 2010 ·ACS Nano ·Brian M. Barth, Rahul Sharma, Erhan İ. Altınoğlu, Thomas T. Morgan, Sriram S. Shanmugavelandy, James M. Kaiser, Christopher O. McGovern, Gail L. Matters, Jill P. Smith, Mark Kester, James H. Adair	113
19	Growth of Human Pancreatic Cancer Is Inhibited by Down-Regulation of Gastrin Gene Expression 2009 ·Pancreas ·Gail L. Matters, John F. Harms, Christopher O. McGovern, Calpurnia Jayakumar, (unknown), Zachary P. Smith, Melissa C. Nelson, (unknown), (unknown), James M. Kaiser, Mark Kester, Jill P. Smith	28
20	The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease 2008 ·Journal of Immunotoxicology ·Gail L. Matters, John F. Harms, Christopher O. McGovern, Leo R. Fitzpatrick, (unknown), (unknown), Jill P. Smith	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact